Medtronic (NYSE:MDT) today announced the launch of its InPen “smart” insulin pen integrated with real-time Guardian Connect continuous glucose monitor (CGM) data.
The Fridley, Minn.-based medtech giant is touting InPen is the first and only FDA-cleared smart insulin pen on the market for people on multiple daily insulin injections. The system is designed to provide real-time glucose readings alongside insulin dose information without switching apps.
Get the full story on our sister site, Drug Delivery Business.